Since inception, Propella Therapeutics, Inc., and its predecessor company Vizuri Health Sciences LLC, have been funded by its founders and associated individuals and entities. Propella was spun-out of Vizuri in 2020 as a stand-alone entity dedicated to the accelerated development of prescription medicines under the FDA 505 (b) (2) regulatory pathway. Our lead product candidate, topical CGS-200-5, has successfully completed a Phase 2 study for the management of pain due to osteoarthritis (OA) of the knee. Earlier-stage programs focused on prostate cancer (PRL-02) and herpes virus infections (PRL-01) will begin clinical studies in 2021.
Propella is seeking likeminded investors who share our vision to bring innovative medicines to market.
The Arthritis Foundation is the arthritis community’s Champion of Yes. The Foundation’s goal is to chart a winning course, guiding families in developing personalized plans for living a full life while striving for a cure. The Arthritis Foundation helps people living with arthritis through its strategic pillars of scientific discovery, help and support, advocacy and access, and juvenile arthritis.
National Cancer Institute (NCI)
Laboratory of Genitourinary Cancer Pathogenesis (LGCP)
The NCI ‘s Laboratory of Genitourinary Cancer Pathogenesis (LGCP) focuses on genitourinary (GU) cancers, especially prostate cancer, with the goal of understanding fundamental processes of cancer pathogenesis and translating this knowledge into clinical applications. Specifically, LGCP includes mechanism-oriented research programs to investigate 1) the action of common prostate cancer genomic mutations, 2) microenvironmental influences on tumor progression and metastasis development, 3) castration resistance and prostate cancer stem cells, and 4) the regulation of responses to cell death pathways.
Joanneum Research (JR)
JR’s Institute for Biomedicine and Health Sciences is a link between basic medical research and industrial applications acting as an interdisciplinary provider of total solutions in the fields of medicine, pharmacy, medical technology and health care research. As a service to the pharmaceutical industry, they investigate the pharmacokinetics (PK) and pharmacodynamics (PD) of new drugs as well as the bioequivalence (BE) of new pharmaceutical formulations. They perform preclinical ex vivo and in vivo, as well as clinical in vivo, studies using their patented Open Flow Microperfusion methodology.
We value and wish to hear from parties who share our motivation to accelerate development of life-changing medicines.
discuss the Propella potential
To learn more about investment or partnering opportunities, contact:
William Moore, PhD
President and CEO